Literature DB >> 11125285

Mutational analysis of the beta-catenin gene in gastric carcinomas.

Y Sasaki1, I Morimoto, M Kusano, M Hosokawa, F Itoh, K Yanagihara, K Imai, T Tokino.   

Abstract

Previous studies reported that mutation of the adenomatous polyposis coli (APC) gene was not observed in the majority of gastric cancers. To evaluate the role of the APC/beta-catenin/Tcf pathway, we analyzed mutations in the beta-catenin gene and the accumulation of beta-catenin protein in gastric carcinomas. An interstitial deletion spanning exon 3 of the beta-catenin gene was observed in 1 of 13 gastric cancer cell lines. No missense mutation was found in these 13 cell lines. Nuclear and/or cytoplasmic localization of beta-catenin was observed in 16 of 70 primary gastric carcinomas by immunohistochemistry, while we found no mutations in exon 3 in 35 carcinoma tissues available for PCR amplification. Our findings suggest that somatic mutations of the beta-catenin gene are rare in human gastric carcinomas and that accumulation of normal beta-catenin protein in a subset of gastric cancers may be due to other mechanisms of its activation. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11125285     DOI: 10.1159/000050606

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  12 in total

Review 1.  Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review.

Authors:  Miguel Angel Chiurillo
Journal:  World J Exp Med       Date:  2015-05-20

2.  Mutation spectrum in the Wnt/β-catenin signaling pathway in gastric fundic gland-associated neoplasms/polyps.

Authors:  Se-Yong Lee; Tsuyoshi Saito; Hiroyuki Mitomi; Yasuhiro Hidaka; Takashi Murakami; Ryosuke Nomura; Sumio Watanabe; Takashi Yao
Journal:  Virchows Arch       Date:  2015-03-29       Impact factor: 4.064

3.  Detection of β-catenin, gastrokine-2 and embryonic stem cell expressed ras in gastric cancers.

Authors:  Fan Zhang; Jian Min Tang; Li Wang; Jing Ying Shen; Lin Zheng; Ping Ping Wu; Mei Zhang; Zhao Wen Yan
Journal:  Int J Clin Exp Pathol       Date:  2010-11-01

4.  Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study.

Authors:  A Gylling; W M Abdel-Rahman; M Juhola; K Nuorva; E Hautala; H J Järvinen; J-P Mecklin; M Aarnio; P Peltomäki
Journal:  Gut       Date:  2007-01-31       Impact factor: 23.059

5.  Genetic and epigenetic characteristics of gastric cancers with JC virus T-antigen.

Authors:  Satoshi Yamaoka; Hiroyuki Yamamoto; Katsuhiko Nosho; Hiroaki Taniguchi; Yasushi Adachi; Shigeru Sasaki; Yoshiaki Arimura; Kohzoh Imai; Yasuhisa Shinomura
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

6.  Mutations in components of the Wnt signaling pathway in gastric cancer.

Authors:  Kai-Feng Pan; Wan-Guo Liu; Lian Zhang; Wei-Cheng You; You-Yong Lu
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

7.  LZTFL1 suppresses gastric cancer cell migration and invasion through regulating nuclear translocation of β-catenin.

Authors:  Linbo Wang; Jufeng Guo; Qinchuan Wang; Jichun Zhou; Chenpu Xu; Rongyue Teng; Yongxia Chen; Qun Wei; Zhi-Ping Liu
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-09       Impact factor: 4.553

8.  Upregulated expression of DIXDC1 in intestinal-type gastric carcinoma: co-localization with β-catenin and correlation with poor prognosis.

Authors:  Lei Wang; Cong Tan; Fan Qiao; Weige Wang; Xiangnan Jiang; Peng Lian; Bin Chang; Weiqi Sheng
Journal:  Cancer Cell Int       Date:  2015-12-18       Impact factor: 5.722

9.  Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer.

Authors:  Chenghai Zhao; Xianmin Bu; Ning Zhang; Wei Wang
Journal:  BMC Cancer       Date:  2009-07-09       Impact factor: 4.430

Review 10.  Winding back Wnt signalling: potential therapeutic targets for treating gastric cancers.

Authors:  Dustin J Flanagan; Elizabeth Vincan; Toby J Phesse
Journal:  Br J Pharmacol       Date:  2017-07-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.